Thymic hyperplasia in a child treated with growth hormone

Objective: To report a case of thymic hyperplasia diagnosed three months after initiation of recombinant human growth hormone (GH) for the treatment of GH deficiency. Design: Retrospective chart review was conducted to evaluate the temporal relationship between treatment with GH and thymic enlargement in a 7-year-old girl who had a history of embryonal rhabdomyosarcoma of the nasopharynx diagnosed at the age of 3 years. Results: The diagnosis of GH deficiency was made based on clinical and auxological criteria, an insufficient response to clonidine-arginine stimulation testing (peak GH level of 4.8 mu g/L) and low insulin-like growth factor I (IGF-1) level (30 ng/mL, -2.7 SD). The patient was started on GH at a dose of 0.3 mg/kg/week. At the initiation of treatment with GH, the baseline growth velocity was 0.8 cm/year (-6.0 SD) and height was 112.5 cm (-1.7 SD). After three months of treatment with GH, her height increased by 4.2 cm (from - 1.7 to - 1.2 SD), and the IGF-1 level from -2.7 SD to -1.1 SD. A chest CT performed at that time for recurrence surveillance showed 89% increase in thymic volume relative to previous scan before treatment with growth hormone. A thoracoscopic biopsy of the thymus was performed and revealed hyperplasia with normal thymic architecture without evidence of malignancy. Conclusions: The timing of the development of thymic hyperplasia, along with data from in vitro and in vivo animal studies showing that GH and IGF- I can directly stimulate growth of the thymus, suggests that GH contributed to the development of thymic hyperplasia in this patient. (c) 2006 Elsevier Ltd. All rights reserved.